LENZ Therapeutics (LENZ) EBITDA (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of EBITDA data on file, last reported at -$44.1 million in Q1 2026.

• On a quarterly basis, EBITDA fell 160.68% year-over-year to -$44.1 million in Q1 2026; TTM through Mar 2026 was -$118.3 million, a 99.05% decrease from a year earlier, with the FY2025 full-year figure at -$91.1 million, down 55.5% from the prior year.
• EBITDA for Q1 2026 stood at -$44.1 million, down from -$38.5 million in the prior quarter.
• Over the last five years, EBITDA for LENZ reached as high as -$12.6 million in Q1 2023 and fell as low as -$44.1 million in Q1 2026.
• Historically, EBITDA has averaged -$21.9 million across 5 years, with a median of -$18.9 million in 2025.
• Across the five-year window, EBITDA slumped 177.09% in 2022 and soared 51.4% in 2023, its largest moves.
• Year by year, EBITDA stood at -$26.8 million in 2022, then grew by 6.59% to -$25.0 million in 2023, then surged by 39.07% to -$15.2 million in 2024, then tumbled by 152.63% to -$38.5 million in 2025, then dropped by 14.75% to -$44.1 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$44.1 million in Q1 2026, -$38.5 million in Q4 2025, and -$18.9 million in Q3 2025.